Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients

Clinical Nephrology

Volumn 65, Issue 3, 2006, Pages 191-202

  Finn, W F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dialysis; End stage renal disease; Hyperphosphatemia; Lanthanum carbonate; Phosphate binder

Indexed keywords

CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CALCIUM BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOTENSION; INCIDENCE; LIVER TOXICITY; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; OUTCOMES RESEARCH; PARATHYROID HORMONE BLOOD LEVEL; PERIPHERAL EDEMA; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 33644786844     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP65191     Document Type: Article

References (23)

1. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
2. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004; 62: 104-115.
3. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int. 2004; Suppl: 90 S39-S45.
4. Damment SJP, Greaves P, Downes N. Lanthanum carbonate (Fosrenol), a novel non-aluminum, non-calcium phosphate binder: toxicology studies. Poster presented at the 36th Annual Meeting of the American Society of Nephrology (ASN). San Diego: 2003. Poster.
5. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003; Suppl 85: S73-S78.
6. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (4 Suppl 3): 1-201.
7. Finn WF, Joy MS, Hladik GA, and the Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004; 62: 193-201.
8. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32 Suppl 3: S112-S119.
9. Genzyme Corporation. Renagel package insert. Cambridge, MA: Genzyme Corporation; 2004.
10. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
11. Gundberg CM. Biochemical markers of bone formation. Clin Lab Med. 2000; 20: 489-501.
12. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100: 8-19.
13. Hutchison AJ, Speake M, Al Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant. 2004; 19: 1902-1906.
14. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003; 42: 96-107.
15. Malluche HH, Wilson R on Behalf of the SPD405-307 Lanthanum Study Group. A 2-year randomized, comparator-controlled trial investigating the effect of lanthanum carbonate on bone. Poster presented at the 3rd World Congress of Nephrology. 2005; Singapore.
16. Marco MP, Muray S, Betriu A et al. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron. 2002 92: 499-500.
17. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997; 29: 496-502.
18. Plone MA, Petersen JS, Rosenbaum DP, Burke SK. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet. 2002; 41: 517-523.
19. Rodriguez M, Felsenfeld AJ, Llach F. Aluminum administration in the rat separately affects the osteoblast and bone mineralization. J Bone Miner Res. 1990; 5: 59-67.
20. Rufino M, de Bonis E, Martin M et al. Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant. 1998; 13 Suppl 3: 65-67.
21. Shire Pharmaceuticals. Fosrenol® package insert. Shire Pharmaceuticals. 2004.
22. US Renal Data System. USRDS: the United States Renal Data System. Am J Kidney Dis. 2003; 42: 1-230
23. Wills MR, Savory J. Aluminum poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet. 1983; 2: 29-34.